RIZE — Rize Oncology Balance Sheet
0.000.00%
Last trade - 00:00- CA$2.27m
- CA$0.68m
Annual balance sheet for Rize Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.18 | 1.8 | 1.36 | 1.16 | 0.346 |
| Net Total Receivables | — | — | — | — | 0.152 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.37 | 1.94 | 1.41 | 1.19 | 0.572 |
| Total Assets | 0.37 | 1.94 | 1.41 | 1.19 | 0.572 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.213 | 0.087 | 0.039 | 0.083 | 0.126 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.213 | 0.087 | 0.039 | 0.083 | 0.126 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.157 | 1.86 | 1.37 | 1.11 | 0.446 |
| Total Liabilities & Shareholders' Equity | 0.37 | 1.94 | 1.41 | 1.19 | 0.572 |
| Total Common Shares Outstanding |